These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

366 related articles for article (PubMed ID: 25833669)

  • 1. Prevention of oxaliplatin-induced peripheral neuropathy by a polyamine-reduced diet-NEUROXAPOL: protocol of a prospective, randomised, controlled, single-blind and monocentric trial.
    Balayssac D; Ferrier J; Pereira B; Gillet B; Pétorin C; Vein J; Libert F; Eschalier A; Pezet D
    BMJ Open; 2015 Apr; 5(4):e007479. PubMed ID: 25833669
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness assessment of riluzole in the prevention of oxaliplatin-induced peripheral neuropathy: RILUZOX-01: protocol of a randomised, parallel, controlled, double-blind and multicentre study by the UNICANCER-AFSOS Supportive Care intergroup.
    Kerckhove N; Busserolles J; Stanbury T; Pereira B; Plence V; Bonnetain F; Krakowski I; Eschalier A; Pezet D; Balayssac D
    BMJ Open; 2019 Jun; 9(6):e027770. PubMed ID: 31182448
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Laser acupuncture attenuates oxaliplatin-induced peripheral neuropathy in patients with gastrointestinal cancer: a pilot prospective cohort study.
    Hsieh YL; Chou LW; Hong SF; Chang FC; Tseng SW; Huang CC; Yang CH; Yang CC; Chiu WF
    Acupunct Med; 2016 Oct; 34(5):398-405. PubMed ID: 27613370
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oxaliplatin-Induced Peripheral Neuropathy and Identification of Unique Severity Groups in Colorectal Cancer.
    Griffith KA; Zhu S; Johantgen M; Kessler MD; Renn C; Beutler AS; Kanwar R; Ambulos N; Cavaletti G; Bruna J; Briani C; Argyriou AA; Kalofonos HP; Yerges-Armstrong LM; Dorsey SG
    J Pain Symptom Manage; 2017 Nov; 54(5):701-706.e1. PubMed ID: 28743660
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomised, placebo-controlled trial assessing the efficacy of an oral B group vitamin in preventing the development of chemotherapy-induced peripheral neuropathy (CIPN).
    Schloss JM; Colosimo M; Airey C; Masci P; Linnane AW; Vitetta L
    Support Care Cancer; 2017 Jan; 25(1):195-204. PubMed ID: 27612466
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of venlafaxine for the prevention and relief of oxaliplatin-induced acute neurotoxicity: results of EFFOX, a randomized, double-blind, placebo-controlled phase III trial.
    Durand JP; Deplanque G; Montheil V; Gornet JM; Scotte F; Mir O; Cessot A; Coriat R; Raymond E; Mitry E; Herait P; Yataghene Y; Goldwasser F
    Ann Oncol; 2012 Jan; 23(1):200-205. PubMed ID: 21427067
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Study protocol: fish oil supplement in prevention of oxaliplatin-induced peripheral neuropathy in adjuvant colorectal cancer patients - a randomized controlled trial. (OxaNeuro).
    Gehr NL; Karlsson P; Timm S; Christensen S; Hvid CA; Peric J; Hansen TF; Lauritzen L; Finnerup NB; Ventzel L
    BMC Cancer; 2024 Feb; 24(1):168. PubMed ID: 38308227
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quantitative Sensory Testing at Baseline and During Cycle 1 Oxaliplatin Infusion Detects Subclinical Peripheral Neuropathy and Predicts Clinically Overt Chronic Neuropathy in Gastrointestinal Malignancies.
    Reddy SM; Vergo MT; Paice JA; Kwon N; Helenowski IB; Benson AB; Mulcahy MF; Nimeiri HS; Harden RN
    Clin Colorectal Cancer; 2016 Mar; 15(1):37-46. PubMed ID: 26337211
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical Course of Oxaliplatin-Induced Neuropathy: Results From the Randomized Phase III Trial N08CB (Alliance).
    Pachman DR; Qin R; Seisler DK; Smith EM; Beutler AS; Ta LE; Lafky JM; Wagner-Johnston ND; Ruddy KJ; Dakhil S; Staff NP; Grothey A; Loprinzi CL
    J Clin Oncol; 2015 Oct; 33(30):3416-22. PubMed ID: 26282635
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is quantitative sensory testing helpful in the management of oxaliplatin neuropathy? a two-year clinical study.
    Delmotte JB; Beaussier H; Auzeil N; Massicot F; Laprévote O; Raymond E; Coudoré F
    Cancer Treat Res Commun; 2018; 17():31-36. PubMed ID: 30343217
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized controlled trial of hand/foot-cooling by hilotherapy to prevent oxaliplatin-related peripheral neuropathy in patients with malignancies of the digestive system.
    Coolbrandt A; Tobback H; Govaerts R; Vandezande L; Vinckx M; Laenen A; Wildiers H; Verslype C; Dekervel J; Van Herpe F; Van Cutsem E
    ESMO Open; 2023 Apr; 8(2):101205. PubMed ID: 37018872
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The association between sociodemographic, clinical, and potentially preventive therapies with oxaliplatin-induced peripheral neuropathy in colorectal cancer patients.
    Hines RB; Schoborg C; Sumner T; Zhu X; Elgin EA; Zhang S
    Support Care Cancer; 2023 Jun; 31(7):386. PubMed ID: 37294347
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Persistent prevention of oxaliplatin-induced peripheral neuropathy using calmangafodipir (PledOx
    Glimelius B; Manojlovic N; Pfeiffer P; Mosidze B; Kurteva G; Karlberg M; Mahalingam D; Buhl Jensen P; Kowalski J; Bengtson M; Nittve M; Näsström J
    Acta Oncol; 2018 Mar; 57(3):393-402. PubMed ID: 29140155
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Topiramate prevents oxaliplatin-related axonal hyperexcitability and oxaliplatin induced peripheral neurotoxicity.
    Alberti P; Canta A; Chiorazzi A; Fumagalli G; Meregalli C; Monza L; Pozzi E; Ballarini E; Rodriguez-Menendez V; Oggioni N; Sancini G; Marmiroli P; Cavaletti G
    Neuropharmacology; 2020 Mar; 164():107905. PubMed ID: 31811874
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neuroprotective effect of reduced glutathione on oxaliplatin-based chemotherapy in advanced colorectal cancer: a randomized, double-blind, placebo-controlled trial.
    Cascinu S; Catalano V; Cordella L; Labianca R; Giordani P; Baldelli AM; Beretta GD; Ubiali E; Catalano G
    J Clin Oncol; 2002 Aug; 20(16):3478-83. PubMed ID: 12177109
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral alpha-lipoic acid to prevent chemotherapy-induced peripheral neuropathy: a randomized, double-blind, placebo-controlled trial.
    Guo Y; Jones D; Palmer JL; Forman A; Dakhil SR; Velasco MR; Weiss M; Gilman P; Mills GM; Noga SJ; Eng C; Overman MJ; Fisch MJ
    Support Care Cancer; 2014 May; 22(5):1223-31. PubMed ID: 24362907
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Goshajinkigan oxaliplatin neurotoxicity evaluation (GONE): a phase 2, multicenter, randomized, double‑blind, placebo‑controlled trial of goshajinkigan to prevent oxaliplatin‑induced neuropathy.
    Kono T; Hata T; Morita S; Munemoto Y; Matsui T; Kojima H; Takemoto H; Fukunaga M; Nagata N; Shimada M; Sakamoto J; Mishima H
    Cancer Chemother Pharmacol; 2013 Dec; 72(6):1283-90. PubMed ID: 24121454
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oxaliplatin-induced peripheral neuropathy's effects on health-related quality of life of colorectal cancer survivors.
    Tofthagen C; Donovan KA; Morgan MA; Shibata D; Yeh Y
    Support Care Cancer; 2013 Dec; 21(12):3307-13. PubMed ID: 23903798
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of donepezil for the treatment of oxaliplatin-induced peripheral neuropathy: DONEPEZOX, a protocol of a proof of concept, randomised, triple-blinded and multicentre trial.
    Kerckhove N; Tougeron D; Lepage C; Pezet D; Le Malicot K; Pelkowski M; Pereira B; Balayssac D
    BMC Cancer; 2022 Jul; 22(1):742. PubMed ID: 35799138
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oxaliplatin-induced neuropathy in colorectal cancer: many questions with few answers.
    Zedan AH; Hansen TF; Fex Svenningsen A; Vilholm OJ
    Clin Colorectal Cancer; 2014 Jun; 13(2):73-80. PubMed ID: 24365057
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.